CN101049360A - Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine - Google Patents
Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine Download PDFInfo
- Publication number
- CN101049360A CN101049360A CN 200710022254 CN200710022254A CN101049360A CN 101049360 A CN101049360 A CN 101049360A CN 200710022254 CN200710022254 CN 200710022254 CN 200710022254 A CN200710022254 A CN 200710022254A CN 101049360 A CN101049360 A CN 101049360A
- Authority
- CN
- China
- Prior art keywords
- group
- eps
- fevervine
- gout
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating gout is prepared from Chinese fevervine herb through extracting.
Description
Technical field
The present invention relates to a kind of newtype drug, treat the Chinese medicine preparation of gout specifically, and the application of fevervine extract in the medicine of preparation treatment gout and hyperuricemia disease.
Background technology
Gout is that long-term purine metabolism obstacle, blood uric acid increase the one group of different substantiality disease that causes tissue injury.Clinical characters is: hyperuricemia, characteristic acute arthritis are shown effect repeatedly, in the leukocyte of knuckle synovia, can find the crystallization of uric acid sodium, tophus forms, and its severe patient can cause joint movement disorder and deformity, the kidney urate calculus and (or) gouty excess of the kidney matter pathological changes.Existence can separately or be united in above-mentioned performance.About 5%-12% hyperuricemia patient can be developed into gout, and its transformation mechanism is not bright, so the boundary of the two is difficult for dividing.Gout not only can be invaded bone and joint, but also involves kidney and cardiovascular system easily.Diseases such as hyperuricemia and primary gout and obesity, hyperlipemia, hypertension, diabetes, atherosclerosis are remarkable positive correlation.Therefore, gout is a kind of serious metabolic disease of harm humans health.
In recent years, along with the variation of people's dietary structure, sugar, fat, protein intake obviously increases, and no matter is the trend that the America and Europe or the prevalence of Asian Peoples's gout have cumulative year after year.Antigout drug can be divided into five classes mainly based on Western medicine according to its model of action at present: 1. suppress granulocyte and soak into medicine, as colchicine; 2. suppress uricopoiesis medicine (xanthine oxidase inhibitor), as allopurinol; 3. promote the urate excretion medicine, as probenecid, benzbromarone etc.; 4. NSAID (non-steroidal anti-inflammatory drug) is as indomethacin, Phenylbutazone, piroxicam, naproxen etc.; 5. glucocorticoids is as prednisone.Owing to 1., 4., 5. be mainly used in the gout acute attack stage, selection 2. on the disease progression different phase, 3. medicine is to alleviate hyperuricemia, and control disease develops.Allopurinol is unique xanthine oxidase inhibitor that uses clinically, suppresses the generation of uric acid, but it has toxic and side effects such as skin allergy, hepatitis, life-threatening super quick allergy syndrome etc., has limited its safe handling to a certain extent.Therefore, seeking novel anti gout and antihyperuricemic disease drug from natural resources still is the focus of research.
Fevervine (Paederia scandens) is the traditional Chinese herbal medicine of China, is Rubiaceae Paederia herbaceous perennial vine, and its root and herb are all pharmaceutically acceptable.Put down in writing according to " book of gathering medicinal herbs ": " fevervine is controlled wind pain acute appendicitis, traumatic injury, stream wind syndrome caused by deficiency fire, furunculosis, gloom-dispelling ".The modern Chinese medicine theory thinks, fevervine is flat, sweet in the mouth, little hardship, goes into liver, spleen channel, and effects such as tool expelling wind and removing dampness, analgesic antidotal, promoting digestion and removing stagnation, promoting blood circulation and detumescence still do not have the relevant report of fevervine treatment gout at present.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine preparation and the application of fevervine extract in the medicine of preparation treatment gout and hyperuricemia for the treatment of gout.
Technical scheme of the present invention is as follows:
A kind of Chinese medicine preparation for the treatment of gout, it is characterized in that containing the fevervine extract for the treatment of effective dose, contain paederoside, fevervine time glycosides, asperuloside, Paederosidie Acid in the described fevervine extract, take off acetyl asperuloside, male fruit acid, sitosterol, fatty acid, aliphatic alcohol and the wet goods composition that volatilizees.
The Chinese medicine preparation of described treatment gout, it is characterized in that it is the fevervine extract and mixes the pharmaceutical preparation that forms with other at acceptable pharmaceutical carrier pharmaceutically that dosage form is said any dosage form on the pharmaceutics: include but not limited to powder, granule, tablet, capsule, pill, drop, soft capsule, leafing agent, solution, suspending agent, syrup, buccal tablets, sublingual lozenge, suppository, injection, ointment.
The Chinese medicine preparation of described treatment gout is characterized in that wherein only containing a kind of effective ingredient of fevervine extract, or contains the multiple effective ingredient that comprises the fevervine extract.
The purposes of fevervine extract is characterized in that being used to prepare the medicine for the treatment of gout and hyperuricemia.
In the Chinese medicine preparation of treatment gout, the fevervine extract can use separately or with the form of pharmaceutical composition, administering mode can be decided as the case may be, and can need the conventional method in field to make form of administration such as suitable mouth, rectally, intramuscular injection according to medicament as required.Its oral or non-oral administration all is safe.Under oral situation, it can be any conventionally form administration, as powder, granule, tablet, capsule, pill, drop, soft capsule, leafing agent, solution, suspending agent, syrup, buccal tablets, sublingual lozenge etc.; When the non-oral administration of this medicine, can adopt any conventionally form, for example suppository, injection are as intravenous injection, ointment, percutaneous dosing, inhalant etc.
The medicine that the present invention prepares gout is to be made of effective site or the multiple active ingredient monomer excipient with solid or liquid, the excipient of solid used herein or liquid is well known in the art, lift several object lessons below, powder is the powder agent that takes orally, and its excipient has lactose, starch, paste essence, calcium carbonate, synthetic or puritan filler aluminum, magnesium oxide, magnesium stearate, sodium bicarbonate, dry yeast etc.; The excipient of solution has water, glycerol, propylene glycol, simple syrup, ethanol, ethylene glycol, Polyethylene Glycol, Sorbitol etc.; The excipient of ointment can use fatty oil.The water-repelling agent or the hydrophilizing agent of combination such as agnolin, vaseline, glycerol, Cera Flava, haze tallow, liquid paraffin, resin, advanced wax.
The dosage of active ingredient of the present invention can be according to the mode of taking, and patient's age and body weight and the degree that is in a bad way change with other similar factor.
By the results of pharmacodynamic test of medicine of the present invention, prove the tangible gout effect of having of fevervine extract, this provides theoretical foundation for clinical treatment gouty disease.Simultaneously, fevervine extract medicine source is wide, good effect, and because the sickness rate of gout is raising year by year, and the fevervine extract is developed to anti-gout novel medical, and good industrialization prospect is arranged, is worth further developmental research.
The specific embodiment
Experiment is to further describe of the present invention below, but does not mean that any limitation of the invention.
Fevervine extract: Paederia Scandens Extract, EPS
Test the inhibitory action of an EPS to rat gouty arthritis due to the micro-crystal type uric acid sodium
1 experiment material
1.1 animal: male rat, body weight 250 ± 20 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Naproxen capsule, Hefei join pharmaceutical Co. Ltd for a long time to be produced, and uric acid sodium (MSU) is produced for sigma company, and the time spent is made into the desired concn suspension with distilled water respectively, and for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Get 60 of male rats, be divided into 6 at random: normal control group, model control group, positive controls naproxen (25mg/kg), three dosage groups of EPS (4.5g/kg, 2.25g/kg, 1.13g/kg), normal control group and model control group are given normal saline.Every day 1 time, in 1 week of successive administration, behind the last administration 1h, the normal control group is given the 50ul normal saline and is injected ankle joint, all the other rats are all annotated people 50ul uric acid sodium (20mg/ml) solution (tried rat right side ankle joint dorsal part with No. 6 entry needles, it is strong inboard to insert people's tibialis from 45 degree directions).Adopt the rat foot claw volumetry, measure cause scorching before and cause scorching back 1,2,4,6, the right back sufficient pawl volume of 8h rat, so that sufficient pawl difference in volume and judges that no difference of science of statistics is arranged as the swelling degree before and after scorching, the result is as shown in table 1.
By the result as seen, MSU causes that rat foot claw swelling reaches the peak in 4h, then alleviates gradually.Compare with model control group, EPS height, middle dosage group can obviously suppress the acute inflammatory reaction of rat foot claw swelling, and its antiinflammatory intensity is obvious before 6h.
Test the preventive and therapeutic effect of two EPS to rabbit gouty arthritis due to the micro-crystal type uric acid sodium
1 experiment material
1.1 animal: rabbit, male, 2.8 ± 0.2 kilograms of body weight, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Naproxen capsule, Hefei join pharmaceutical Co. Ltd for a long time to be produced, and uric acid sodium (MSU) is produced for sigma company, and the time spent is made into the desired concn suspension with distilled water respectively, and for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Get 36 of male rabbits, be divided into normal control group, model control group, EPS (2.5,1.25,0.625g/kg) dosage group, positive drug naproxen group (18mg/kg) at random.Gastric infusion is 7 days respectively, 30min after the last administration, except that the normal control group, under aseptic condition, inject 0.3mlMSU (100mg/ml) suspension in the knee joint for every group and cause inflammation. cause scorching back 5h and put to death rabbit, collect hydrarthrosis, carry out numeration of leukocyte, and get synovial membrane and carry out histological examination and the results are shown in Table 2,3.The result shows: compare with matched group, EPS height, middle dosage group can obviously reduce rabbit and cause numeration of leukocyte in the scorching arthroedema, obviously alleviate the inflammatory reaction degree of synovial tissue of joint.
Table 1 fevervine extract to uric acid sodium cause the rat gouty arthritis inhibitory action (x ± s, n=10)
| Group | Dosage (mg/kg) | Cause scorching back different time foot pawl swelling degree (ml) | ||||
| 1h | 2h | 4h | 6h | 8h | ||
| Normal control group model matched group naproxen EPS | / / 25 4500 2250 1130 | 0.28± 0.12** 0.65± 0.20 0.29± 0.14** 0.28± 0.13** 0.33± 0.17* 0.51± 0.11 | 0.31± 0.16** 0.68± 0.14 0.36± 0.15** 0.31± 0.15** 0.37± 0.17** 0.58± +0.10 | 0.40± 0.21** 0.86± 0.30 0.43± 0.11** 0.43± 0.22** 0.50± 0.18** 0.68± 0.15 | 0.35± 0.12 0.62± 0.33 0.37± 0.16 0.40± 0.25 0.49± 0.23 0.53± 0.10 | 0.35± 0.24* 0.57± 0.22 0.36± 0.18* 0.38± 0.12 0.47± 0.21 0.46± 0.14 |
Compare with model control group: * P＜0.05, * * P＜0.01
Table 2EPS to the influence of rabbit joint numeration of leukocyte due to the MSU (x ± s, n=10)
| Group | Dosage (mg/kg) | Numeration of leukocyte (k/ml, x ± s) |
| Normal control group model matched group naproxen EPS | / / 18 2500 1250 625 | (2.0±0.3)×106** (5.2±0.9)×106 (2.5±0.6)×106** (3.1±0.5)×106** (3.4±0.4)×106* (4.5±0.8)×106 |
Compare with model control group: * P＜0.05, * * P＜0.01
Table 3EPS is to the influence of rabbit gouty gonarthritis synovial membrane
| Group | Dosage (mg/kg) | Congested | The edema degree | Cell infiltration |
| Normal control group model matched group naproxen EPS | / / 18 2500 1250 625 | - + - - - + | - +++ ± + + ++ | - +++ + ± + + |
Test the inhibitory action of white mice auricle edema due to the three EPS xylol
1 experiment material
1.1 animal: Kunming mouse, male and female half and half, body weight 20 ± 2 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Naproxen capsule, Hefei join pharmaceutical Co. Ltd for a long time to be produced, and the time spent is made into the desired concn suspension with distilled water respectively, and for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Get 50 of Kunming kind white mice, be divided into normal control group, EPS (6.3,3.15,1.57g/kg) dosage group at random, positive drug naproxen group (35mg/kg, irritate stomach once in d14), continuous irrigation stomach 14d, 1h after the last administration, ear two sides, a left side with 100% dimethylbenzene 0.03ml/ only is coated with, auris dextra is put to death mice for contrast behind the 2h, cut two ears along the auricle baseline, with ￠ 9mm card punch, preparation mice auricle is weighed, with the difference of two ear weight as the swelling degree.And compare between organizing, the results are shown in Table 4.Table 4 result shows that EPS height, middle dosage group can suppress the swelling of the inductive mice auricle of dimethylbenzene.
The influence of the inductive mice ear degree of table 4EPS xylol (x ± s, n=10)
| Group | Dosage (mg/kg) | Swelling degree (mg) | Suppression ratio (%) |
| Normal control group naproxen EPS | / 35 6300 3150 1570 | 12.49±2.81 6.45±1.08** 7.29±2.45** 8.67±2.48* 9.28±2.56 | 48.35 41.63 30.58 25.70 |
Compare with the normal control group: * P＜0.05, * * P＜0.01
Test four EPS and mice acetic acid is caused the influence of writhing response
1 experiment material
1.1 animal: Kunming mouse, male and female half and half, body weight 20 ± 2 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Naproxen capsule, Hefei join pharmaceutical Co. Ltd for a long time to be produced, and the time spent is made into the desired concn suspension with distilled water respectively, and for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Get 50 of Kunming mouses, divide 5 groups at random: normal control group, EPS (6.3,3.15,1.57g/kg) dosage group, positive drug naproxen group (35mg/kg, 1h filling stomach once before the d14 experiment), 10 every group.1h began experiment after continuous irrigation stomach 14d, d14 irritated stomach.After the last administration 1 hour, inject 0.6% acetum 0.4ml/ Mus in mouse peritoneal, observe the number of times that writhing response takes place for mice in 15 minutes after 5 minutes, and between organizing relatively, the results are shown in Table 5.The result shows that the high, medium and low dosage group of EPS all can suppress the mouse writhing reaction.
The inhibitory action that table 5EPS reacts mouse writhing (x ± s, n=10)
| Group | Dosage (mg/kg) | 15min turns round the body number of times |
| Normal control group naproxen EPS | / 35 6300 3150 1570 | 59.0±7.7 22.5±4.3** 31.7±9.6** 38.4±11.7** 45.4±5.3* |
Compare with the normal control group: * P＜0.05, * * P＜0.01
Test five EPS and mice formalin is caused the influence of pain model
1 experiment material
1.1 animal: Kunming mouse, male and female half and half, body weight 20 ± 2 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Naproxen capsule, Hefei join pharmaceutical Co. Ltd for a long time to be produced, and the time spent is made into the desired concn suspension with distilled water respectively, and for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Get 50 of Kunming mouses, divide 5 groups at random: normal control group, EPS (6.3,3.15,1.57g/kg) dosage group, positive drug naproxen group (35mg/kg, 1h filling stomach once before the d14 experiment), 10 every group.1h began experiment after continuous irrigation stomach 14d, d14 irritated stomach.After the last administration 1 hour to mice left hind toes subcutaneous injection 2.5% formalin solution 15 μ l, immediately in the glass container as for ￠ 40cm, 0-5min (I phase) licks the sufficient cumulative time with the interior mice of 15-35min (II mutually) after writing down injection of formalin respectively, and compare between organizing, the results are shown in Table 6.The result shows that EPS height, middle dosage group all can suppress the I phase reaction, and the II phase reaction is also had obvious inhibitory action.
The inhibitory action that table 6EPS tests mice formalin (x ± s, n=10)
| Group | Dosage (mg/kg) | I phase reaction (s) | II phase reaction (s) |
| Normal control group naproxen EPS | 35 6300 3150 1570 | 23.8±12.2 25.1±14.3 15.1±9.7* 13.5±8.9** 22.2±7.6 | 95.8±20.7 34.1±10.2** 52.4±12.3** 58.9±13.7** 71.2±18.0 |
Compare with the normal control group: * P＜0.05, * * P＜0.01
Test six EPS to the contract influence of end reaction of mice hot water
1 experiment material
1.1 animal: Kunming mouse, male and female half and half, body weight 20 ± 2 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Naproxen capsule, Hefei join pharmaceutical Co. Ltd for a long time to be produced, and the time spent is made into the desired concn suspension with distilled water respectively, and for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Kunming mouse, male and female half and half, 18-22g, in 48 ℃ of waters bath with thermostatic control of the vertical immersion of its tail point, immersion length is 3cm, writes down tail incubation period (TCL) that contracts and is threshold of pain index, twice of administration before measurement (5min at interval), with its average as the basic threshold of pain, (5s＜TCL＜30s) 55 is divided into five groups at random: normal control group, EPS (6.3,3.15,1.57g/kg) dosage group, positive drug naproxen group (35mg/kg to screen qualified mice, before the d14 experiment, irritate stomach once), 10 every group.1h began experiment after continuous irrigation stomach 14d, d14 irritated stomach.1h measures the end reaction incubation period of contracting of mice after the administration, and between organizing relatively, the results are shown in Table 7.The result shows that EPS height, middle dosage group can prolong mice and contract tail incubation period.
The table 7EPS to mice hot water contract the tail method influence (x ± s, n=10)
| Group | Dosage mg/kg | End reaction incubation period (s) contracts | |
| Before the administration | 1h after the administration | ||
| Normal control group naproxen EPS | 35 6300 3150 1570 | 6.3±1.2 6.8±1.1 7.1±1.5 6.2±0.9 7.1±1.4 | 6.8±1.0 17.9±3.1** 10.2±2.7* 9.4±1.6* 7.3±1.5 |
Compare with the normal control group: * P＜0.05, * * P＜0.01
Test seven EPS to influence to the reaction of mice hot plate
1 experiment material
1.1 animal: Kunming mouse, female, body weight 20 ± 2 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Naproxen capsule, Hefei join pharmaceutical Co. Ltd for a long time to be produced, and the time spent is made into the desired concn suspension with distilled water respectively, and for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Kunming mouse, be placed on 50 ± 0.5 ℃ of thermostat metal plates of preheating, measure the basic threshold of pain of each mice, screen 55 of qualified mices (5-30s), be divided into five groups at random: normal control group, EPS (6.3,3.15,1.57g/kg) dosage group, positive drug naproxen group (35mg/kg irritates stomach once before the d14 experiment), 10 every group.1h began experiment after continuous irrigation stomach 14d, d14 irritated stomach.Respectively at after the administration 1/2,1,2,4h measures its threshold of pain.And compare between organizing, the results are shown in Table 8.The result shows that the high, medium and low dosage group of EPS all obviously prolongs the mice hot plate and adds the sufficient response latency. administration 0.5h onset, the 1h analgesic activity is the strongest.
Table 8EPS to the influence of mice hot plate method (x ± s, n=10)
| Group | Dosage mg/kg | Basis (s) | 1/2h(s) | 1h(s) | 2h(s) | 4h(s) |
| Normal control group naproxen EPS | 35 6300 3150 1570 | 21.8± 4.2 17.8± 2.0 18.9± 2.2 21.0± 2.5 18.7± 2.4 | 21.4± 5.3 29.9± 9.2* 31.8± 4.9* 24.6± 5.6* 29.7± 12.3* | 21.6± 5.2 39.6± 9.8** 39.3± 8.9** 37.1± 8.6** 33.6± 9.4** | 21.8± 4.9 41.5± 11.4** 36.4± 9.5** 31.6± 9.8** 30.0± 8.3* | 22.1± +4.5 29.2± 8.0* 31.5± 7.4** 28.3± 10.1 28.2± 6.8 |
Compare with the normal control group: * P＜0.05, * * P＜0.01
Test the influence of eight EPS to hyperuricemia mice hyperuricemia due to the Oteracil Potassium
1 experiment material
1.1 animal: Kunming mouse, male and female half and half, body weight 20 ± 2 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Allopurinol tablet (0.1g/ sheet, lot number: 061001 Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd. produces), Oteracil Potassium is produced for ALDRICH company, and the time spent is made into the desired concn suspension with distilled water respectively, for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Get 60 of Kunming mouses, divide 6 groups at random, normal control group, model control group, EPS (6.30,3.15,1.57g/kg) dosage group and allopurinol 0.04g/kg group.Every day gastric infusion once, normal control group and model control group are given normal saline, continuous 14 days. last day, other respectively organized mice 1h ip Oteracil Potassium 300mg/kg before the administration respectively except that the normal control group.Behind the administration 1h, get blood through mouse orbit, survey blood uric acid content, and compare between organizing, the result is as shown in table 9.The result shows that model control group mice blood uric acid and normal control group relatively have three dosage groups of significant differences .EPS that the blood uric acid of falling effect is all arranged, height, and middle dosage group and model control group more all have significant difference.
Table 9EPS to the influence of hyperuricemia mice serum uric acid level (x ± s, n=10)
| Group | Dosage (g/kg) | Serum uric acid level (mg/l) |
| Normal control group model matched group allopurinol EPS | 0.04 6.30 3.15 1.57 | 18.46±6.87** 30.15±10.13 10.35±4.68** 14.98±3.62** 13.16±4.14** 21.44±9.56* |
Compare with model control group: * P＜0.05, * * P＜0.01
Test nine EPS and yeast extract is caused the influence of hyperuricemia mice blood uric acid and xanthine oxidase activity
1 experiment material
1.1 animal: Kunming mouse, male and female half and half, body weight 20 ± 2 grams, all animals are all purchased the animal center in Medical University Of Anhui.
1.2 medicine: EPS, this chamber self-control.Allopurinol tablet (0.1g/ sheet, lot number: 061001 Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd. produces), yeast extract (production of Beijing extensive and profound in meaning star biotechnology responsibility company limited), time spent is made into the desired concn suspension with distilled water respectively, for gastric infusion, matched group is given simultaneously with the volume distilled water.
2 experimental techniques and result
Get 60 of Kunming mouses, be divided into normal control group, model group, three dosage groups of EPS, positive control allopurinol group at random.The yeast gastric infusion, 30g/kg, continuous 14 days.Gastric infusion is respectively organized in beginning in the 5th day.Pluck eyeball on the 14th day and get blood, survey serum uric acid level.Get mouse liver simultaneously, survey xanthine oxidase activity, the result is as shown in table 10.The result shows that model control group mice blood uric acid and normal control group relatively have significant differences.Among the EPS, low dose group can significantly reduce the uric acid level of hyperuricemia mice due to the yeast extract; The activity of the xanthine oxidase of hyperuricemia mice due to all right significantly inhibition of the middle dosage group yeast extract.
Table 10EPS to the influence of hyperuricemia mice serum uric acid level (x ± s, n=10)
| Group | Dosage (g/kg) | Serum uric acid level (mg/l) | Xanthine oxidase activity (U/L) |
| Normal control group model matched group allopurinol EPS | 0.04 6.30 3.15 | 40.15±2.16** 51.83±12.30 39.10±1.74** 45.37±2.14 41.09±1.23** | 72.72±4.02 79.27±4.57 62.90±3.79** 81.69±8.76 58.72±6.49** |
| 1.57 | 43.56±3.36** | 75.46±7.63 |
Compare with model control group: * P＜0.05, * * P＜0.01
Claims (4)
1, a kind of Chinese medicine preparation for the treatment of gout, it is characterized in that containing the fevervine extract for the treatment of effective dose, contain paederoside, fevervine time glycosides, asperuloside, Paederosidie Acid in the described fevervine extract, take off acetyl asperuloside, male fruit acid, sitosterol, fatty acid, aliphatic alcohol and the wet goods composition that volatilizees.
2, the Chinese medicine preparation of treatment gout according to claim 1, it is characterized in that it is the fevervine extract and mixes the pharmaceutical preparation that forms with other at acceptable pharmaceutical carrier pharmaceutically that dosage form is said any dosage form on the pharmaceutics: include but not limited to powder, granule, tablet, capsule, pill, drop, soft capsule, leafing agent, solution, suspending agent, syrup, buccal tablets, sublingual lozenge, suppository, injection, ointment.
3, the Chinese medicine preparation of treatment gout according to claim 1 is characterized in that wherein only containing a kind of effective ingredient of fevervine extract, or contains the multiple effective ingredient that comprises the fevervine extract.
4, the purposes of fevervine extract is characterized in that being used to prepare the medicine for the treatment of gout and hyperuricemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710022254 CN101049360A (en) | 2007-05-10 | 2007-05-10 | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710022254 CN101049360A (en) | 2007-05-10 | 2007-05-10 | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101049360A true CN101049360A (en) | 2007-10-10 |
Family
ID=38781096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710022254 Pending CN101049360A (en) | 2007-05-10 | 2007-05-10 | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101049360A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890033A (en) * | 2009-05-20 | 2010-11-24 | 苏州颐华生物医药技术有限公司 | Application of paederosidic acid used for preparing analgesic drugs and/or anti-inflammatory drugs |
| CN102846784A (en) * | 2011-06-23 | 2013-01-02 | 宁波大昌药业有限公司 | Paederia scandens water extract, and preparation method and application thereof |
| CN103735999A (en) * | 2014-01-23 | 2014-04-23 | 吴占凤 | Traditional Chinese medicinal preparation for treating gout and preparation method thereof |
| CN106727602A (en) * | 2016-12-29 | 2017-05-31 | 广西中医药大学 | Application of the ursolic acid in treatment gout medicine is prepared |
| CN112047988A (en) * | 2019-06-05 | 2020-12-08 | 宁波大昌药业有限公司 | Paederoside monomer compound, preparation method and application thereof |
-
2007
- 2007-05-10 CN CN 200710022254 patent/CN101049360A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890033A (en) * | 2009-05-20 | 2010-11-24 | 苏州颐华生物医药技术有限公司 | Application of paederosidic acid used for preparing analgesic drugs and/or anti-inflammatory drugs |
| CN102846784A (en) * | 2011-06-23 | 2013-01-02 | 宁波大昌药业有限公司 | Paederia scandens water extract, and preparation method and application thereof |
| CN102846784B (en) * | 2011-06-23 | 2014-10-01 | 宁波大昌药业有限公司 | Paederia scandens water extract, and preparation method and application thereof |
| CN103735999A (en) * | 2014-01-23 | 2014-04-23 | 吴占凤 | Traditional Chinese medicinal preparation for treating gout and preparation method thereof |
| CN103735999B (en) * | 2014-01-23 | 2015-12-09 | 吴占凤 | A kind of Chinese medicine preparation and preparation method for the treatment of gout |
| CN106727602A (en) * | 2016-12-29 | 2017-05-31 | 广西中医药大学 | Application of the ursolic acid in treatment gout medicine is prepared |
| CN112047988A (en) * | 2019-06-05 | 2020-12-08 | 宁波大昌药业有限公司 | Paederoside monomer compound, preparation method and application thereof |
| CN112047988B (en) * | 2019-06-05 | 2023-02-03 | 宁波大昌药业有限公司 | Paederoside monomer compound, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN101049360A (en) | Preparation of Chinese traditional medicine for treating gout disease, and application of extractive of Chinese feveruine | |
| CN1698858A (en) | Pharmaceutical composition for treating acute gout and its extraction method | |
| CN1923193A (en) | Application of cumarin kind compound in preparation of antiphlogistic and analgetic medicine | |
| CN1824256A (en) | Chinese medicinal preparation for treating osteopathia and its preparation method | |
| CN1186336C (en) | Prepn and application in preparing medicine of fraxinus general coumarin | |
| CN105687274B (en) | New application of acanthopanax giraldii harms wood heart or extract thereof | |
| CN1824204A (en) | Medicinal composition for treating acute urarthritis and its preparation method | |
| CN1739678A (en) | Medicine for treating pain caused by wind, cold and wetness evils and its prepn | |
| CN1220496C (en) | Bougie for treating virus hepatitis and preparing method thereof | |
| CN1857492A (en) | Qingxie preparation and its preparing process | |
| CN105497167A (en) | New application of radix ranunculi ternate in preparation of medicine for treating and/or preventing ulcerative colitis | |
| CN1415303A (en) | Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia | |
| CN1823980A (en) | Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method | |
| CN1301728C (en) | Chinese medicine compound preparation for treating osteoarthropathy and its preparation method | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method | |
| CN1679673A (en) | Isatis root drops and preparation thereof | |
| CN1785410A (en) | Preparation method of ready prepared chinese medicinal granules for treathing pains | |
| CN1824075A (en) | Medicinal composition for treating hemicrania and its application | |
| CN1824253A (en) | Medicine for treating fatty liver and its preparation method | |
| CN101062108A (en) | Medicinal composition for treating dysmenorrhea and preparation process thereof | |
| CN1267130C (en) | Chinese five-kind compound medicine for treating premenstrual symptomgroup and its preparation method | |
| CN1660329A (en) | Medication of possessing effect for reducing fat and treating fatty liver | |
| CN114272254A (en) | Application of combination of glycyrrhetinic acid and paeoniflorin in treatment of liver injury and hepatic fibrosis | |
| CN1899428A (en) | Chinese medicine preparation for treating pain and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20071010 |